Literature DB >> 18562517

Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.

Andrew E Armitage1, Aris Katzourakis, Tulio de Oliveira, John J Welch, Robert Belshaw, Kate N Bishop, Beatrice Kramer, Andrew J McMichael, Andrew Rambaut, Astrid K N Iversen.   

Abstract

The human polynucleotide cytidine deaminases APOBEC3G (hA3G) and APOBEC3F (hA3F) are antiviral restriction factors capable of inducing extensive plus-strand guanine-to-adenine (G-to-A) hypermutation in a variety of retroviruses and retroelements, including human immunodeficiency virus type 1 (HIV-1). They differ in target specificity, favoring plus-strand 5'GG and 5'GA dinucleotide motifs, respectively. To characterize their mutational preferences in detail, we analyzed single-copy, near-full-length HIV-1 proviruses which had been hypermutated in vitro by hA3G or hA3F. hA3-induced G-to-A mutation rates were significantly influenced by the wider sequence context of the target G. Moreover, hA3G, and to a lesser extent hA3F, displayed clear tetranucleotide preference hierarchies, irrespective of the genomic region examined and overall hypermutation rate. We similarly analyzed patient-derived hypermutated HIV-1 genomes using a new method for estimating reference sequences. The majority of these, regardless of subtype, carried signatures of hypermutation that strongly correlated with those induced in vitro by hA3G. Analysis of genome-wide hA3-induced mutational profiles confirmed that hypermutation levels were reduced downstream of the polypurine tracts. Additionally, while hA3G mutations were found throughout the genome, hA3F often intensely mutated shorter regions, the locations of which varied between proviruses. We extended our analysis to human endogenous retroviruses (HERVs) from the HERV-K(HML2) family, finding two elements that carried clear footprints of hA3G activity. This constitutes the most direct evidence to date for hA3G activity in the context of natural HERV infections, demonstrating the involvement of this restriction factor in defense against retroviral attacks over millions of years of human evolution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562517      PMCID: PMC2519685          DOI: 10.1128/JVI.00584-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  HIV-1 genome nuclear import is mediated by a central DNA flap.

Authors:  V Zennou; C Petit; D Guetard; U Nerhbass; L Montagnier; P Charneau
Journal:  Cell       Date:  2000-04-14       Impact factor: 41.582

2.  The Staden package, 1998.

Authors:  R Staden; K F Beal; J K Bonfield
Journal:  Methods Mol Biol       Date:  2000

3.  Initial sequencing and analysis of the human genome.

Authors:  E S Lander; L M Linton; B Birren; C Nusbaum; M C Zody; J Baldwin; K Devon; K Dewar; M Doyle; W FitzHugh; R Funke; D Gage; K Harris; A Heaford; J Howland; L Kann; J Lehoczky; R LeVine; P McEwan; K McKernan; J Meldrim; J P Mesirov; C Miranda; W Morris; J Naylor; C Raymond; M Rosetti; R Santos; A Sheridan; C Sougnez; Y Stange-Thomann; N Stojanovic; A Subramanian; D Wyman; J Rogers; J Sulston; R Ainscough; S Beck; D Bentley; J Burton; C Clee; N Carter; A Coulson; R Deadman; P Deloukas; A Dunham; I Dunham; R Durbin; L French; D Grafham; S Gregory; T Hubbard; S Humphray; A Hunt; M Jones; C Lloyd; A McMurray; L Matthews; S Mercer; S Milne; J C Mullikin; A Mungall; R Plumb; M Ross; R Shownkeen; S Sims; R H Waterston; R K Wilson; L W Hillier; J D McPherson; M A Marra; E R Mardis; L A Fulton; A T Chinwalla; K H Pepin; W R Gish; S L Chissoe; M C Wendl; K D Delehaunty; T L Miner; A Delehaunty; J B Kramer; L L Cook; R S Fulton; D L Johnson; P J Minx; S W Clifton; T Hawkins; E Branscomb; P Predki; P Richardson; S Wenning; T Slezak; N Doggett; J F Cheng; A Olsen; S Lucas; C Elkin; E Uberbacher; M Frazier; R A Gibbs; D M Muzny; S E Scherer; J B Bouck; E J Sodergren; K C Worley; C M Rives; J H Gorrell; M L Metzker; S L Naylor; R S Kucherlapati; D L Nelson; G M Weinstock; Y Sakaki; A Fujiyama; M Hattori; T Yada; A Toyoda; T Itoh; C Kawagoe; H Watanabe; Y Totoki; T Taylor; J Weissenbach; R Heilig; W Saurin; F Artiguenave; P Brottier; T Bruls; E Pelletier; C Robert; P Wincker; D R Smith; L Doucette-Stamm; M Rubenfield; K Weinstock; H M Lee; J Dubois; A Rosenthal; M Platzer; G Nyakatura; S Taudien; A Rump; H Yang; J Yu; J Wang; G Huang; J Gu; L Hood; L Rowen; A Madan; S Qin; R W Davis; N A Federspiel; A P Abola; M J Proctor; R M Myers; J Schmutz; M Dickson; J Grimwood; D R Cox; M V Olson; R Kaul; C Raymond; N Shimizu; K Kawasaki; S Minoshima; G A Evans; M Athanasiou; R Schultz; B A Roe; F Chen; H Pan; J Ramser; H Lehrach; R Reinhardt; W R McCombie; M de la Bastide; N Dedhia; H Blöcker; K Hornischer; G Nordsiek; R Agarwala; L Aravind; J A Bailey; A Bateman; S Batzoglou; E Birney; P Bork; D G Brown; C B Burge; L Cerutti; H C Chen; D Church; M Clamp; R R Copley; T Doerks; S R Eddy; E E Eichler; T S Furey; J Galagan; J G Gilbert; C Harmon; Y Hayashizaki; D Haussler; H Hermjakob; K Hokamp; W Jang; L S Johnson; T A Jones; S Kasif; A Kaspryzk; S Kennedy; W J Kent; P Kitts; E V Koonin; I Korf; D Kulp; D Lancet; T M Lowe; A McLysaght; T Mikkelsen; J V Moran; N Mulder; V J Pollara; C P Ponting; G Schuler; J Schultz; G Slater; A F Smit; E Stupka; J Szustakowki; D Thierry-Mieg; J Thierry-Mieg; L Wagner; J Wallis; R Wheeler; A Williams; Y I Wolf; K H Wolfe; S P Yang; R F Yeh; F Collins; M S Guyer; J Peterson; A Felsenfeld; K A Wetterstrand; A Patrinos; M J Morgan; P de Jong; J J Catanese; K Osoegawa; H Shizuya; S Choi; Y J Chen; J Szustakowki
Journal:  Nature       Date:  2001-02-15       Impact factor: 49.962

4.  G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo.

Authors:  Tara L Kieffer; Patty Kwon; Richard E Nettles; Yefei Han; Stuart C Ray; Robert F Siliciano
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.

Authors:  Edmund N C Newman; Rebecca K Holmes; Heather M Craig; Kevin C Klein; Jaisri R Lingappa; Michael H Malim; Ann M Sheehy
Journal:  Curr Biol       Date:  2005-01-26       Impact factor: 10.834

6.  APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.

Authors:  Cécile Esnault; Odile Heidmann; Frédéric Delebecque; Marie Dewannieux; David Ribet; Allan J Hance; Thierry Heidmann; Olivier Schwartz
Journal:  Nature       Date:  2005-01-27       Impact factor: 49.962

7.  Human LINE retrotransposons generate processed pseudogenes.

Authors:  C Esnault; J Maestre; T Heidmann
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

8.  Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome.

Authors:  S R Stetor; J W Rausch; M J Guo; J P Burnham; L R Boone; M J Waring; S F Le Grice
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

9.  Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.

Authors:  James A Dutko; Alexandra Schäfer; Alison E Kenny; Bryan R Cullen; M Joan Curcio
Journal:  Curr Biol       Date:  2005-04-12       Impact factor: 10.834

10.  Sequence and transcriptional analyses of the fish retroviruses walleye epidermal hyperplasia virus types 1 and 2: evidence for a gene duplication.

Authors:  L A LaPierre; D L Holzschu; P R Bowser; J W Casey
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  56 in total

1.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution.

Authors:  Shai Carmi; George M Church; Erez Y Levanon
Journal:  Nat Commun       Date:  2011-11-01       Impact factor: 14.919

Review 3.  Powerful mutators lurking in the genome.

Authors:  Vincent Petit; Jean-Pierre Vartanian; Simon Wain-Hobson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-03-12       Impact factor: 6.237

4.  Footprint of APOBEC3 on the genome of human retroelements.

Authors:  Firoz Anwar; Miles P Davenport; Diako Ebrahimi
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 5.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

6.  Human Endogenous Retrovirus Type K (HERV-K) Particles Package and Transmit HERV-K-Related Sequences.

Authors:  Rafael Contreras-Galindo; Mark H Kaplan; Derek Dube; Marta J Gonzalez-Hernandez; Susana Chan; Fan Meng; Manhong Dai; Gilbert S Omenn; Scott D Gitlin; David M Markovitz
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

7.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.

Authors:  Kieran Gillick; Darja Pollpeter; Prabhjeet Phalora; Eun-Young Kim; Steven M Wolinsky; Michael H Malim
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

9.  Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.

Authors:  Patric Jern; Rebecca A Russell; Vinay K Pathak; John M Coffin
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

10.  The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Authors:  Nicoletta Casartelli; Florence Guivel-Benhassine; Romain Bouziat; Samantha Brandler; Olivier Schwartz; Arnaud Moris
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.